Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. by Chelsea Caspell-Garcia, Tanya Simuni, Duygu Tosun-Turgut, I-Wei Wu, Yu Zhang, Mike Nalls, Andrew Singleton, Leslie A Shaw, Ju-Hee Kang, John Q Trojanowski, Andrew Siderowf, Christopher Coffey, Shirley Lasch, Dag Aarsland, David Burn, Lana M Chahine, Alberto J Espay, Eric D Foster, Keith A Hawkins, Irene Litvan, Irene Richard, Daniel Weintraub, Parkinson’s Progression Markers Initiative (PPMI)

Get full text

Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the M... by Jared C. Robins, M.D., Andrew F. Khair, Ph.D., M.B.A., Eric A. Widra, M.D., Michael M. Alper, M.D., Winnie W. Nelson, Pharm.D., M.S., M.B.A., Eric D. Foster, Ph.D., Anshul Sinha, B.Tech., Masakazu Ando, Ph.D., Patrick W. Heiser, Ph.D., Gaurang S. Daftary, M.D., M.B.A.

Get full text